ProCE Banner Activity

IMvigor210: Predictors of Response to Atezolizumab in mUC

Slideset Download
Conference Coverage
PD-L1 expression, TCGA subtype, and mutational load were independent predictors of atezolizumab response in patients with mUC, and response prediction improved significantly with combination of these markers.

Released: June 14, 2016

Expiration: June 13, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals